U.S. FDA APPROVES PFIZER’S XELJANZ FOR THE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS

▴ us-fda-approves-pfizers-xeljanz-for-the-treatment-of-juvenile-idiopathic-arthritis
Pfizer Inc. announced XELJANZ (tofacitinib) for the treatment of children 2 years and older with active polyarticular course juvenile idiopathic arthritis

Pfizer Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight. This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.

“Polyarticular course juvenile idiopathic arthritis, or pcJIA, is debilitating as it can cause significant joint pain and limit participation in child-appropriate activities,” said Dr. Hermine Brunner, Director of the Division of Rheumatology at Cincinnati Children’s Hospital Medical Center and Scientific Director of the Pediatric Rheumatology Collaborative Study Group. “Although there are already several advanced treatments available, tofacitinib will be an appealing new option given it does not require injections or infusions. These can be quite burdensome to both children with pcJIA and their caretakers. The FDA approval of Xeljanz for pcJIA is positive news for this community as it provides a new advanced treatment option is an oral formulation.”

This approval was based on data from a Phase 3 study including two phases: an 18-week open-label, run-in phase (including 225 patients), followed by a 26-week double-blind, placebo-controlled, randomized, withdrawal phase (including 173 patients) for a total duration of 44 weeks. The study evaluated the efficacy and safety of tofacitinib taken as either a 5 mg tablet or as a 1 mg/mL oral solution twice daily based on the subject’s body weight (<40 kg for the oral solution and or patient preference span The trial met its primary endpoint showing that in patients with pcJIA who achieved juvenile idiopathic arthritis (JIA) American College of Rheumatology (ACR) 30 response at the end of the run-in phase, the occurrence of disease flare in patients treated with tofacitinib (31 percent; n/N=27/88) was statistically significantly (p=0.0007) lower than patients treated with placebo (55 percent; n/N=47/85) at week 44. In this study, disease flare was defined as a 30 percent or more worsening in at least three of the six variables of the JIA ACR core set, with no more than one of the remaining JIA core response variables improving by 30 percent or more (outcome measures used in JIA clinical trials) after randomization.

In general, the types of adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients. Please see important safety information below.

“Many children and adolescents living with polyarticular course juvenile idiopathic arthritis, or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community,” said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “This approval, which is the fourth indication for XELJANZ, reinforces its utility in the treatment of immune-mediated inflammatory conditions and further demonstrates our expertise in JAK science.”

XELJANZ oral solution is anticipated to be available by the end of Q1 2021. XELJANZ 5 mg tablets are available immediately.

Tags : #LatestPharmaNewsSep28 #LatestPfizerNewsSep28 #Treatmentforchildidiopathicarthritis #juvenilearthritis

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Reforming global financial architecture is critical for gender equality and right to healthJuly 14, 2025
Francesco Arezzo takes office as president of Rotary InternationalJuly 14, 2025
CBM India Highlights Inclusive Eye Health at VISION 2020: The Right to Sight – INDIA 19th Annual ConferenceJuly 14, 2025
Crompton Introduces Ameo Fresh Nutri Blender, Reinforcing Its Promise of ‘Healthy Choices Made Easy’July 14, 2025
NMC Notifies Medical Institutions (Qualifications of Faculty) Regulations, 2025 to Expand Medical Education Capacity and Strengthen Faculty Availability July 14, 2025
India’s Roads, India’s Pain: Healing Beyond the HospitalJuly 14, 2025
When Weathers Go Deadly: Role Of Climate Change In Stimulating The Proliferation Of Disease-carrying VectorsJuly 14, 2025
India’s Hidden Health Emergency: Climate Pressures on WellbeingJuly 14, 2025
The Silent Urgency: Why Geriatric Health Homes Can’t Wait AnymoreJuly 14, 2025
Rewiring the Brain: How Neuroscience Apps Are Changing Stroke RecoveryJuly 14, 2025
Healing Happens at Home: How Community Care Breaks the Cycle of Repeat Hospital TripsJuly 14, 2025
The Future Is Hands-On: How AR Is Quietly Reshaping Physical TherapyJuly 14, 2025
Flying Lifelines: Why Medical Drones are Changing Supply Chains in SilenceJuly 14, 2025
The Silent Hunger Are Well Fed Indian Teens Actually MalnourishedJuly 14, 2025
Richest 1% people have enough new wealth to end annual poverty 22 times overJuly 11, 2025
Fermenta Signs Strategic MoU with NIFTEM-T to Strengthen India’s Food Fortification LandscapeJuly 11, 2025
Sarvodaya Hospital, Greater Noida West, Launches Next-Gen Fully Active Robotic System for Joint ReplacementJuly 10, 2025
Children Dazzle the Stage at Faridabad Talent Hunt at Asian Institute of Medical SciencesJuly 10, 2025
From Macro to Mandate: How India's Affluent Investors are Positioning for Global ShiftsJuly 10, 2025
Actress-turned-Entrepreneur raises alarm over hidden pet health crisis in IndiaJuly 10, 2025